A ground-breaking study, conducted by researchers from the University of Virginia, Mount Sinai, the University of Michigan, ...
Prostate cancer is the second leading cause of cancer death among American men. A recent study, conducted by researchers from ...
Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...
Siemens Healthineers, India’s recent partnership with HealthCare Global Enterprises (HCG), is aimed to revolutionize cancer ...
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately ...
In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...
Clarity Pharmaceuticals Dr Alan Taylor Catherine Strong Executive Chairman Investor/Media Relations ataylor@claritypharm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback